Currently, a phase III trial that compared zongertinib (BI 1810631) to the SoC (platinum + pemetrexed + pembrolizumab) is ongoing in previously untreated patients with HER2 MUT (in TKD) NSCLC, and the primary endpoint is BICR-PFS (Beamion LUNG-2, NCT06151574). Here, ERBB2 is linked to non-small cell lung carcinoma.